Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)

NCT02357147 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

124

Enrollment

INDUSTRY

Sponsor class

Stopped Due to business reasons

Conditions

Mesothelioma, Malignant

Interventions

DRUG: Placebo
DRUG: Amatuximab
DRUG: Pemetrexed
DRUG: Cisplatin

Sponsor

Morphotek